<DOC>
	<DOCNO>NCT02956499</DOCNO>
	<brief_summary>First In Human ( FIH ) , randomize , double-blind , placebo-controlled single ascend dose ( SAD ) multiple ascend dose ( MAD ) escalation study approximately 80 subject . The SAD portion study enroll six cohort eight healthy subject per cohort , total approximately 48 healthy subject . The MAD portion study enroll four cohort eight healthy subject per cohort , total approximately 32 healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics APX001 Administered Intravenously</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<criteria>Women childbearing potential must agree avoid pregnancy study use contraception least 2 week start study 3 month last dose study drug . Males partner ( ) childbearing potential must agree use appropriate barrier contraception screen period 3 month last dose study drug . Screening hematology , clinical chemistry , coagulation urinalysis consistent overall good health . No significantly abnormal finding physical examination , ECG vital sign . Willing able provide write informed consent . Any uncontrolled active major systemic disease include , limited : cardiovascular , pulmonary , gastrointestinal , metabolic , urogenital , neurological , immunological , psychiatric , neoplastic disorder metastatic potential . History presence malignancy within past year . Subjects successfully treat recurrence basal cell carcinoma skin carcinoma insitu cervix may enrol . Use prescription medication within 14 day prior first dose study drug throughout study . Use nonprescription overthecounter medication within 7 day prior first dose study drug throughout study . Positive result follow Screening laboratory test : serum pregnancy test , urine alcohol test , urine drug abuse , hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>